Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.44 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8035118 | 0.93 | CYP3A4 (0.58) | CYP3A4HTR6HRH1HDAC1HDAC6 | |
| SCHEMBL10155062 | 0.86 | ADRA2A (0.49) | HTR6HRH1CA1CA2HDAC1 | |
| SCHEMBL8038616 | 0.85 | CA1 (0.65) | HTR6CA1CA2HDAC1HDAC6 | |
| SCHEMBL10155065 | 0.84 | HTR6 (0.51) | CYP3A4HTR6HRH1CA1CA2 | |
| SCHEMBL10127966 | 0.80 | HTR6 (0.57) | HTR6HRH1CA1CA2HDAC1 | |
| SCHEMBL14302050 | 0.79 | HRH1 (0.67) | CYP3A4HTR6HRH1 | |
| SCHEMBL24479764 | 0.79 | HDAC1 (0.58) | HTR6CA1CA2HDAC1HDAC6 | |
| SCHEMBL10155031 | 0.78 | BCHE (0.66) | HDAC1HDAC6 | |
| SCHEMBL8036733 | 0.78 | HTR6 (0.71) | HTR6HRH1 | |
| SCHEMBL4892790 | 0.78 | HDAC1 (0.50) | CYP3A4HTR6HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| EP-2062895-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008024029-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ABCG2, HTR3C, AADAC | CYP3A4 74/4885HTR6 117/4885HRH1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.